Protak Scientific to Attend Pharma Integrates

Protak Scientific has announced it will be attending Pharma Integrates 2017.

The event will be taking place from the 15 November to 16 November at the Grange City Hotel in London. Protak Scienfic is a proud sponsor of this prestigious event and the company’s CEO Phillip Godden will take his seat as a panelist on the second day of the conference.

About Pharma Integrates 2017

Supported previously by in excess of 70 prestigious speakers and 300 senior pharmaceutical industry executives, a programme of interviews and interactive panel discussions this year will focus on the strategic issues facing the drug manufacturing sector and play a vital role in shaping pharma’s future.

Topics for debate with panelists at this year’s event include:

  • Rethinking pharmaceutical productivity
  • The evolving role of contract development and manufacturing organisations (CDMO)
  • The changing demographic of drugs, patient centricity, and serialisation

With representation from the pharmaceutical community including biotechs, small-to-medium enterprises (SME), small-to-large pharmaceutical companies, contract research organisations (CRO), CDMOs, consultants, patient groups, and academics, this not-to-be-missed meeting also offers unparalleled networking opportunities.

Protak’s Phill Godden as a Key Panelist

Alongside sponsoring the event, Phill Godden will take an active part in a live debate as a panelist during the ‘De-risking Pharma: From Policies and Guidelines to Production – Risk management is a valuable component of an effective quality system’ facilitated by global vice-president Martin Lush.

Here is a summary of the debate:

Risk is the probability of occurrence of harm and the severity of that harm. However, achieving a shared understanding of the application of risk management is difficult. In relation to pharmaceuticals, although there are a variety of stakeholders, including patients and medical practitioners as well as government and industry, the protection of the patient by managing the risk to quality should be considered of prime importance. Given that risk and the effective prediction of risk needs intuitive data interpretation, the panel will look beyond the numbers and examine how pharma views, manages and assesses risk.

Phill will be explaining how enzyme indicator decontamination validation technology can significantly reduce risk for pharma companies and help manage it going forwards with industry-changing implications.

Protak Scientific hopes to see you at Pharma Integrates this year at what is shaping up to be a fantastic pharma event for the whole industry.

More About This Company